BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 5,219,492 shares of Aura Biosciences Inc. common stock as of the September 30, 2026 triggering event date.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficially owning 5,219,492 shares of Aura Biosciences Inc. common stock, representing 5.03% of the class.
  • Sole voting power: BlackRock reported sole power to vote or direct the vote of 5,144,654 shares.
  • Sole dispositive power: BlackRock reported sole power to dispose or direct the disposition of all 5,219,492 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Triggering event date: The date of event requiring the filing was September 30, 2026.
  • Filer type: BlackRock is identified as a parent holding company (type "HC"), incorporated in Delaware, with principal offices at 50 Hudson Yards, New York, NY 10001.

BlackRock's Schedule 13G Filing on Aura Biosciences Common Stock

BlackRock, Inc. filed a Schedule 13G disclosing a 5.03% beneficial ownership position in Aura Biosciences Inc. (CUSIP 05153U107), a company headquartered at 80 Guest Street, Boston, MA 02135. According to the filing, the triggering event occurred on September 30, 2026, and the statement was signed on October 27, 2026 by Spencer Fleming, Managing Director of BlackRock.

The filing states that the reported holdings reflect securities "beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates." The filing further notes that it "does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units" in accordance with SEC Release No. 34-39538 (January 12, 1998). Subsidiary identification is provided in Exhibit 99, attached to the filing.

Regarding dividend and sale proceeds interests, the filing discloses that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of AURA BIOSCIENCES INC." However, the filing states that "no one person's interest in the common stock of AURA BIOSCIENCES INC is more than five percent of the total outstanding common shares." BlackRock certified that the securities were "acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

BlackRock, Inc. disclosed in a Schedule 13G that it beneficially owns 5,219,492 shares, or 5.03%, of Aura Biosciences Inc. common stock as of September 30, 2026, with sole voting power over 5,144,654 shares and sole dispositive power over all 5,219,492 shares.